Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab

🩺 Protocol Summary

This study is a mechanistic randomized controlled trial that investigates whether inhibition of tumor necrosis factor signaling via intravenous infusion of infliximab improves psychomotor speed and executive functioning in depressed individuals who exhibit an inflammatory phenotype.

Primary Research Facility: Massachusetts General Hospital (Boston, Massachusetts)

Review these 3 basic logistical and protocol criteria extracted from the public NIH record. (This is a preliminary logistical checklist, not an official clinical eligibility determination).

Diagnosed with, undergoing evaluation for, or seeking treatment related to Depressive Disorder, Major?

🔍 Study Population / Focus Area (Source: Protocol Primary Condition)

Aged between 25 Years and 50 Years?

🔍 Protocol Specified Age Range: 25 Years to 50 Years

Able to attend required clinic visits at Massachusetts General Hospital (Boston, Massachusetts)?

🔍 Logistical Requirement: Site at Massachusetts General Hospital

📍 Primary Site Map

Site: Massachusetts General Hospital — Boston, Massachusetts

💰 Clinical Trial Costs & Insurance Coverage

Coverage for clinical trial participation varies depending on your health insurance policy, state legislation, and whether specific procedures are investigational research or routine medical care. Under federal law (Affordable Care Act § 2709), health insurers generally cannot drop coverage or refuse to pay for routine patient care costs incurred in approved clinical trials.

💡 Always ask the study coordinator for the trial's official Informed Consent Form, which outlines all sponsor-funded research items versus procedures billed to your insurance.